CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Finan

CEL-SCI Corporation today reported financial results for the quarter ended March 31, 2023, as well as key clinical and corporate developments.


Clinical and Corporate Developments include:



In... | June 14, 2023

Related Keywords

Vienna , Wien , Austria , Virginia , United States , Baltimore , Maryland , Canada , American , Geert Kersten , Eyal Talor , Health Canada , Securities Exchange , European Congress On Head Neck Oncology , Exchange Commission , European Medicines Agency , National Comprehensive Cancer Network , European Union , Drug Administration , Corporate Developments , Conditional Marketing , Scientific Officer , Interleukin Injection , European Congress , Neck Oncology , Production Act , Defense Production , Leukocyte Interleukin , Orphan Drug , Securities Act , Securities Exchange Act ,